SCA
TEVA icon

Snowden Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Snowden Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.15M Buy
63,441
+2,145
+3% +$71.4K 0.05% 345
2026
Q1 		$1.85M Buy
61,296
+30,302
+98% +$975K 0.05% 355
2025
Q4 		$967K Sell
30,994
-7,358
-19% -$181K 0.03% 539
2025
Q3 		$775K Sell
38,352
-1,241
-3% -$21.8K 0.02% 605
2025
Q2 		$664K Buy
39,593
+3,710
+10% +$59.9K 0.02% 655
2025
Q1 		$552K Buy
35,883
+3,320
+10% +$59.3K 0.02% 698
2024
Q4 		$718K Sell
32,563
-4,350
-12% -$79.1K 0.02% 624
2024
Q3 		$665K Buy
36,913
+5,285
+17% +$92.5K 0.02% 647
2024
Q2 		$514K Sell
31,628
-1,568
-5% -$24.2K 0.02% 737
2024
Q1 		$468K Buy
33,196
+4,124
+14% +$52K 0.01% 788
2023
Q4 		$304K Buy
29,072
+129
+0.4% +$1.2K 0.01% 900
2023
Q3 		$295K Buy
28,943
+18,587
+179% +$173K 0.01% 866
2023
Q2 		$78K Buy
+10,356
New +$84K ﹤0.01% 1147
2022
Q1 		– Sell
-41
Closed – – 1961
2021
Q4 		$0 Buy
+41
New +$370 ﹤0.01% 2150

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Snowden Capital Advisors's TEVA Position: Q2 2026 in Review

Snowden Capital Advisors increased its Teva Pharmaceuticals (TEVA) stake by 3.5% in Q2 2026, buying an estimated $71.4K and bringing the position to 63,441 shares worth $2.15M. The position accounts for 0.05% of the portfolio, ranked #345.

Snowden Capital Advisors first reported a position in TEVA in Q4 2021 and has held it in 14 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Snowden Capital Advisors held 63,441 shares of Teva Pharmaceuticals worth $2.15M as of Q2 2026.
  • Snowden Capital Advisors bought 2,145 Teva Pharmaceuticals shares in Q2 2026, an estimated $71.4K.
  • Teva Pharmaceuticals made up 0.05% of Snowden Capital Advisors's portfolio in Q2 2026, its #345 holding.
  • Snowden Capital Advisors first reported a position in Teva Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.